A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

In addition to determining the hormone receptor and HER2 protein status, healthcare teams use the TNM system to identify the ...

The PATHWAY anti-HER2 (4B5) test includes a scoring algorithm that helps identify ‘low expressors’ of HER2, which assists pathologists in identifying those within the lower HER2 bracket who ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...